Catalyst settles Lupin patent litigation; generic FIRDAPSE launch no earlier than Feb 2035

CATALYST PHARMACEUTICALS, INC.

Lupin granted license to market generic FIRDAPSE beginning February 25, 2035, if FDA-approved.
All ongoing patent litigation between Catalyst/SERB and Lupin in New Jersey terminated.
Prior settlements with Teva and Inventia for FIRDAPSE generics already in place.
Pending patent litigation against Hetero for FIRDAPSE's Orange Book-listed patents continues.
Settlement will be submitted to FTC and DOJ for review as required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.